Introduction {#Sec1}
============

At least one third of the world\'s population is supposed to be sensitive to salt \[[@CR32]\], i.e., arterial hypertension occurs in response to the daily ingestion of large amounts of sodium, a habit widely spread in our societies \[[@CR19]\]. Sodium is bound, osmotically inactive, to the negatively charged proteoglycans in the dermis \[[@CR30]\] and endothelial glycocalyx (eGC) \[[@CR1]\]. Sodium overload damages the eGC \[[@CR24]\], thus diminishing endothelial sodium buffer capacity. Deterioration of the eGC allows sodium exiting the blood vessel lumen more readily via endothelial sodium channels \[[@CR17], [@CR26]\]. As a consequence, sodium spends more time in the extracellular space before being finally cleared by the kidneys \[[@CR16], [@CR22]\]. This delayed sodium excretion leads in the long term to sodium deposition in the body, thereby damaging various tissues \[[@CR12], [@CR14]\]. Based on this concept, the salt provocation test was developed which quantifies vascular sodium sensitivity in vivo \[[@CR21]\]. Vascular sodium sensitivity, inversely related to endothelial sodium buffer capacity, characterizes the quality of the endothelial glycocalyx. Recently, it has been realized that the glycocalyx of erythrocytes (red blood cells (RBC)) reflects some specific surface properties of endothelial cells \[[@CR20]\]. In more details, RBC allowing to physically interacting ("[drag force treatment](#Sec4){ref-type="sec"}") with the endothelial surface in vitro acquire characteristics of the endothelial surface layer. For example, when the endothelial surface layer is experimentally depleted of negative charges---heparan sulfate shedding by the application of the enzyme heparinase---and then RBC allowed to interact for some hours, the RBC glycocalyx is found shed after such a drag force experiment \[[@CR20]\]. This observation led to the conclusion that the vascular salt sensitivity could be indirectly measured by evaluating the erythrocyte salt sensitivity (ESS). A method (salt blood test (SBT)) was developed based on the sodium sensitivity of the RBC zeta potential \[[@CR9], [@CR10]\]. As a proof of principle, the hawthorn-derived compound WS 1442 known to improve endothelial function, in particular the endothelial glycocalyx \[[@CR2], [@CR26]\], was applied in vitro to test whether the SBT "reports" such changes.

Methods {#Sec2}
=======

Principle and procedure of the SBT {#Sec3}
----------------------------------

Experimental steps 1--3 are documented in Fig. [1a--c](#Fig1){ref-type="fig"}. In detail, 2 ml of blood is drawn from volunteers by venous puncture using heparinized monovettes (Sarstedt Company, Sarstedt, Germany). Blood is transferred in 2-ml plastic vials (Eppendorf AG, Hamburg, Germany) and centrifuged at 1,800 × *g* for 5 min. Plasma and buffy coat are removed, and erythrocytes were washed two times in 30 ml of HEPES-buffered (10 mM HEPES = 2-(4-(2-hydroxyethyl)-1-piperazinyl)-ethane sulfonic acid) sodium chloride (150 mM NaCl) including 1 % bovine serum albumin (PAA Clone, Coelbe, Germany). This amount of serum is necessary for proper shielding of the glycocalyx. For a single measurement, 80 μl of washed RBC is suspended in 120 μl NaCl solution (fixed hematocrit, 0.4) containing 3 % dextran (Sigma 4486, MW 70,000 D). Dextran is adsorbed to the RBC surface triggering RBC aggregation (Fig. [1d, e](#Fig1){ref-type="fig"}). This phenomenon is called "macromolecular bridging," indicating that the adhesion forces between RBC overcome the electrostatic repulsive forces \[[@CR9], [@CR10]\]. NaCl concentrations were varied between 50 and 150 mM as appropriate. Sucrose at various amounts was added for maintaining constant osmolality. The test solutions containing varying NaCl concentrations, varying sucrose concentrations, and a fixed concentration of dextran (3 %) are called "Na^+^ cocktails" throughout the paper. Hematocrit capillary tubes (Safecap P75-2000; length 75 mm; Scholz Company, Neubiberg, Germany) were filled by capillary forces with the respective RBC suspensions as appropriate. Hematocrit capillary tubes, closed at the lower end, were put on stands in an upright position (Fig. [2](#Fig2){ref-type="fig"}). RBC sedimentation rates were measured at appropriate time intervals. The dimensionless ESS values of the individual blood samples were calculated as the ratio of the respective RBC sedimentation velocities in 150 and 125 mM Na^+^ cocktail (ESS = L~150~/L~125~). It should be mentioned that a single ESS measurement needs only about 200 μl blood which can be obtained from a puncture of the fingertip. The SBT was performed at ambient temperature. pH values of the Na^+^ cocktails were around 7.4 (due to the endogenous buffering power of hemoglobin at the fixed hematocrit of 0.4).Fig. 1Theory and practice of the salt blood test. From venipuncture to measurement (**a**--**c**). Theory underlying slow and fast erythrocyte (RBC) sedimentation rate (**d**, **e**)Fig. 2Time dependence of the erythrocyte sedimentation rate. RBC were suspended in a 150 mM sodium cocktail (fixed hematocrit = 0.40; see "[Methods](#Sec2){ref-type="sec"}")

Drag force treatment {#Sec4}
--------------------

Endothelial monolayers (human Eahy629 cell line) were cultured for 4 days on the bottom of 75-cm^2^ culture flasks \[[@CR4], [@CR15], [@CR18]\] in the absence (control) and presence of the vasoprotective *Crataegus* extract WS 1442 (10 μg/ml) \[[@CR2]\]. WS 1442 is known to improve glycocalyx function in vitro \[[@CR26]\]. After this period, the culture medium was replaced by whole blood (2.5 ml per flask) taken from volunteers (heparinized monovettes; Sarstedt Company, Sarstedt, Germany). The flasks, mounted on a shaker (4 shifts per min, 7° angle), were placed in a cell culture incubator (37 °C, 5 % CO~2~) and rocked for 3 h so that the RBC could mechanically interact with the surface of the endothelial cell layer. This procedure named drag force treatment was described in detail recently \[[@CR20]\].

Results {#Sec5}
=======

In contrast to the standard erythrocyte sedimentation rate (ESR) which is performed in whole blood and strongly dependent on any inflammation-relevant proteins in the plasma phase \[[@CR27]\], the sedimentation rate used for ESS measurements is independent of any proteins, but strongly dependent on the NaCl concentration of the electrolyte solution in which the erythrocytes have been suspended. In particular, sedimentation rate depends on the RBC zeta potential \[[@CR10]\] and, thus, on the RBC glycocalyx. Since Na^+^ neutralizes the negative charges of the RBC surface, sedimentation rate reflects the Na^+^ buffer capacity of the RBC glycocalyx. As mentioned above, dextran is needed in all solutions; otherwise, aggregation does not occur. In pilot studies, we found out that the most suitable molecular mass of the dextran is 70,000 D, and the most adequate concentration is 3 %. This is in good agreement with a previous study \[[@CR10]\]. Figure [2](#Fig2){ref-type="fig"} shows the time dependence of the RBC sedimentation rate. Initial sedimentation rates are quite linear, but they saturate later on. This is due to the fact that a hematocrit of 0.40 was used so that after long time periods (hours), virtually all RBC, not only the large RBC aggregates, concentrate in the lower part of the tube. Therefore, the 60-min values were chosen for analysis. Figure [3](#Fig3){ref-type="fig"} shows the dependence of the erythrocyte sedimentation on NaCl concentration. Ion strength, and in particular the cation Na^+^, determines sedimentation velocity. The reason why the 125 and 150 mM Na^+^ concentrations have been chosen for the SBT were as follows: The RBC glycocalyx is treated as a Na^+^ buffer. At too low Na^+^ concentrations (below 100 mM), the negative charges of the RBC glycocalyx are heavily undersaturated, making the test insensitive (i.e., the zeta potential is at its maximum). At too high Na^+^ concentrations (beyond 150 mM), the negative charges are completely saturated again, making the test insensitive. Also, it was tried to use NaCl concentrations close to the physiological range. This strategy includes isosmotic conditions (appropriate addition of sucrose to the low Na^+^ solutions) and "normal" osmolality (about 300 mOsm) of the electrolyte solutions. Figure [4](#Fig4){ref-type="fig"} displays two representative measurements. From the respective supernatants, ESS could be calculated. The ESS on the left side of Fig. [4](#Fig4){ref-type="fig"} was 2.2, indicating that RBC sedimentation rate was 2.2 times larger in 150 mM Na^+^ than the sedimentation rate in 125 mM Na^+^. The ESS on the right side of Fig. [4](#Fig4){ref-type="fig"} was 5.8, indicating that RBC sedimentation rate was 5.8 times larger in 150 mM Na^+^ than that in 125 mM Na^+^. Thus, ESS of blood no. 2 was more than twice as high as the ESS of blood no. 1. In a series of control experiments, the heparan sulfate residues of the RBC glycocalyx were enzymatically removed by heparinase I incubation \[[@CR20]\], and then, ESS was measured. In six experiments, ESS increased only by about 13 % (from 2.6 ± 0.12 to 3.0 ± 0.14), indicating that not only heparan sulfate residues but also other negatively charged (and heparinase-insensitive) components of the glycocalyx contribute to the sodium-dependent sedimentation rate.Fig. 3Dependence of the length of the RBC-free supernatant on time and NaCl concentration. Osmolality is kept constant at 300 mOsm by adding appropriate amounts of sucrose. The 60-min value is used for evaluating the erythrocyte sodium sensitivityFig. 4ESS measurements indicating weak erythrocyte Na^+^ sensitivity (blood no. 1) and strong erythrocyte Na^+^ sensitivity (blood no. 2). *ESS* erythrocyte sodium sensitivity

Figure [5](#Fig5){ref-type="fig"} displays ESS measured in 61 healthy volunteers of similar age. The frequency distribution indicates two ESS peaks, one at about 3 and another one at about 5. Figure [6](#Fig6){ref-type="fig"} shows these data in more detail. Forty-six percent (28 out of 61) of the study participants exhibited an ESS of at least 20 % below average. Twenty-eight percent (17 out of 61) of the study participants exhibited an ESS of at least 20 % above average. Figure [7](#Fig7){ref-type="fig"} shows that there is no significant gender difference of the respective ESS. It is worth mentioning here that the SBT has been performed in all experiments at a fixed hematocrit (0.40; see "[Methods](#Sec2){ref-type="sec"}"). Taken together, the data indicate that there is a wide range of ESS (from 2 to 8) in the normal population. It should be mentioned that at least five individuals (red columns in Fig. [6](#Fig6){ref-type="fig"}) were on low-salt diets (for no obvious reason, they indicated this explicitly in a questionnaire). Remarkably, the ESS of all five of them was found in the "weakly salt-sensitive" group.Fig. 5Frequency distribution of the erythrocyte sodium sensitivity in a cohort of 61 study participants. Two peaks are visibleFig. 6Erythrocyte sodium sensitivity (triple measurements) of the same study participants as displayed in Fig. [7](#Fig7){ref-type="fig"}. The overall mean value is 4.3 ± 0.19 (*n* = 61). Five study participants explicitly indicated to be on a low-salt diet (*red columns*)Fig. 7Erythrocyte sodium sensitivity (triple measurements) of the same study participants as displayed in Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}. Here, the data (displayed as *box plots*) are split into male and female groups, respectively

To test whether the RBC surface (i.e., the RBC glycocalyx) suffers when blood is rhythmically dragged across the surface of an endothelial monolayer and whether the expected shedding of the RBC glycocalyx could be prevented (and thereafter verified by the SBT), endothelial monolayers were incubated for 4 days with and without 10 μg/ml WS 1442, a hawthorn extract rich in polyphenols \[[@CR26]\]. After this period of incubation, drag force treatment was applied (see "[Methods](#Sec2){ref-type="sec"}"). The blood overlaying the monolayers was analyzed (performing the SBT) after a 3-h period of drag force treatment. Figure [8](#Fig8){ref-type="fig"} shows the results. ESS analyzed from these blood samples was 5.8 ± 0.48 (control; *n* = 12, mean ± standard error of the mean (SEM)) and 4.5 ± 0.31 (WS 1442; *n* = 12, mean ± SEM). Taken together, the erythrocyte glycocalyx is less shed (−21 %) during drag force treatment by pretreating the endothelium in culture with WS 1442. These data support previous findings, namely, that (a) WS 1442 protects the endothelial glycocalyx, and (b) the ESS reports surface properties of the endothelium with which the blood has been interacting before.Fig. 8Erythrocyte sodium sensitivity measured in RBC harvested from blood overlays after drag force treatment. *Control* no pretreatment. *WS 1442* 4-day pretreatment of the endothelium (in culture) with 10 μg/ml of hawthorn extract WS 1442. A number of measurements are indicated in *columns*. The *inset* shows two culture flasks with endothelial monolayers and blood overlays, located on a shaker, indicating that the blood underwent drag force treatment before the SBT was performed

Discussion {#Sec6}
==========

Arterial hypertension and related vascular diseases have high mortality rates worldwide. One of the major risk factors is high sodium intake \[[@CR19]\]. Obviously, there is an imbalance between sodium intake and renal sodium excretion. Salt sensitivity, i.e., the development of hypertension in response to salt, differs among people. The reasons for the different salt sensitivities are largely unknown. It could be related to the intrinsic ability of the kidneys to excrete sodium \[[@CR7]\], to the limited storage capacities of the skin and muscle \[[@CR14]\] or to a variable sodium buffer capacity of the vasculature \[[@CR24]\]. There are reports that a single salty meal elevates plasma sodium for a few millimoles per liter which has a measureable impact on blood pressure \[[@CR29]\] and endothelial cell function \[[@CR25]\]. Possibly, there is a sodium sensor in vascular endothelium \[[@CR23]\]. A candidate could be the epithelial sodium channel (ENaC). This channel not only controls renal sodium excretion but also regulates the function of vascular endothelium \[[@CR11]\]. Obviously, at least in vitro endothelial sodium sensitivity is linked to endothelial ENaC activity and the function of the endothelial glycocalyx \[[@CR15], [@CR24]\]. According to this concept, the so-called salt provocation test (SPT) was developed \[[@CR21]\]. The SPT is an in vivo test which quantifies vascular salt sensitivity. In principle, blood pressure is measured after an oral sodium load in the presence and absence of a sodium channel blocker. The SPT evaluates the sodium buffer capacity of the endothelial glycocalyx and, hence, the vascular salt sensitivity of the individual. Although the design of the SPT is quite straightforward, two separate sessions are necessary, each with repetitive blood pressure measurements over 1 h, an oral salt load, and the application of a sodium blocker. Therefore, it appeared attractive to develop a blood-based in vitro test system which should allow the evaluation of vascular sodium sensitivity. As described recently by means of atomic force microscopy imaging techniques, RBC "reflect" properties of the endothelial surface \[[@CR20]\]. In detail, when heparan sulfate residues are enzymatically removed from the endothelial glycocalyx, then RBC---upon physical interaction---also lose these key glycocalyx components. This observation, namely, that the surface of RBC obviously "memorizes" the surface of the endothelium, led us to conclude that it should be sufficient to functionally test for the properties of the RBC and thus get insight into the properties of the respective endothelium.

The SBT is based on the sodium-dependent RBC zeta potential \[[@CR9], [@CR10]\]. Its magnitude is directly related to the negative surface charges. Besides sialic acids \[[@CR5]\], heparan sulfate residues \[[@CR3], [@CR13], [@CR31]\] are supposed to contribute to the RBC zeta potential. They preferentially bind sodium \[[@CR1]\]. ESR is used as a quantitative measure for the sodium-dependent zeta potential \[[@CR9], [@CR10]\]. In contrast to standard ESR used as a nonspecific test for inflammatory or tumorous processes in clinical medicine \[[@CR6]\], the SBT is performed in plasma-free electrolyte solution. Besides various concentrations of NaCl, only sucrose (for osmolality reasons) and dextran (triggering aggregation) are present in the Na^+^ cocktails. Therefore, the key variable in the RBC suspensions is Na^+^ which preferentially binds to the heparan sulfate residues.

Two different Na^+^ cocktails are sufficient for performing the SBT. The 125 mM Na^+^ cocktail sets the reference value of the ESR. The 150 mM Na^+^ cocktail sets the upper limit. The dimensionless ESS (Na^+^~150~/Na^+^~125~) is a measure for the salt sensitivity of an individual. It would have the value "1" when the increase of Na^+^ from 125 to 150 mM would not change the zeta potential at all. This would indicate "no sodium sensitivity," a theoretical value that will never occur. A value above 1 indicates "sodium sensitivity," i.e., as larger is this value as more sensitive to sodium is the individual\'s vasculatory system (i.e., RBC and endothelium).

One of the aims of this study was to provide, as a first step, a "reference value" of sodium sensitivity expressed as ESS. Therefore, we performed the SBT in a cohort of 61 healthy young individuals. Although the number of study participants is rather low and thus the interpretation of the data is limited, there are two peaks in ESS. This could not only be due to a genetic predisposition \[[@CR28]\] but also due to distinct differences in lifestyle \[[@CR8]\]. Possibly, the left peak includes individuals with a "weak" sensitivity to sodium, while the right peak includes individuals with a "marked" sensitivity to sodium (see Fig. [5](#Fig5){ref-type="fig"}). Gender differences cannot explain these two peaks.

The SBT will gain a medical relevance only if the concept, namely, that the sodium buffer capacity of the endothelial glycocalyx (related to the inverse of ESS) can be indeed evaluated, is proven, at least in an in vitro experiment. This led us to perform "drag force" experiments in combination with the vasoprotective compound WS 1442. This *Crataegus* extract is known to improve endothelial function \[[@CR2]\] and specifically interacts with the endothelial glycocalyx. At least in vitro, WS 1442 has been shown to unfold ("swell") the glycocalyx and lowers endothelial sodium permeability \[[@CR26]\]. Indeed, ESS significantly decreased by 21 % when the endothelium was pretreated for several days with this compound. Taken together, we assume a mechanism as follows:

Treatment of the endothelium with WS 1442 in vitro swells the endothelial glycocalyx \[[@CR26]\]. This improves electrical surface negativity and, thus, endothelial sodium buffer capacity \[[@CR24]\]. During drag force treatment, erythrocytes mechanically interact. By these means, the RBC surfaces "acquire" properties of the endothelial surface, i.e., their sodium-dependent zeta potentials rise. This results in a decrease of ESS.

Although this is only a first step in the proof of this concept, it opens some interesting perspectives. Sodium sensitivity, at the level of the vascular system, is probably not a "constant" parameter of an individual but is rather a variable that can be (negatively or positively) influenced. This view could make the SBT as a potentially valuable test system in the control of medical measures undertaken to improve vascular function.
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